Skip to main content
Immunovia logo

Immunovia — Investor Relations & Filings

Ticker · IMMNOV ISIN · SE0006091997 LEI · 549300KHWL6KK1XGUO81 ST Human health and social work activities
Open in API
Filings indexed 374 across all filing types
Latest filing 2025-06-24 Major Shareholding Noti…
Country SE Sweden
Listing ST IMMNOV

About Immunovia

https://immunovia.com/

Immunovia is a diagnostics company focused on revolutionizing the early detection of pancreatic cancer. Its primary product is the PancreaSure test, a simple blood test designed to detect pancreatic cancer at Stage 1 and 2 with high accuracy. The test is intended for annual surveillance of individuals at elevated risk due to family history or genetic mutations. PancreaSure functions by detecting proteins and other biomarkers indicative of pancreatic cancer growth. The company's mission is to improve survival rates for this highly lethal cancer by enabling diagnosis at its earliest, most treatable stages, offering a convenient alternative to invasive imaging procedures.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 1% confidence The document details a change in shareholding percentage ('Innehavare', 'Andel', 'Aktier') for a specific entity ('Avanza Bank Holding AB för Försäkringsaktiebolaget Avanza Pension') related to the issuer ('Immunovia AB (publ)'). Key indicators are the transaction type ('Sälj' - Sell), the resulting shareholding percentage (9.94711%), and the context of reporting changes in significant ownership thresholds ('Gränsvärde för antal aktier 10 %'). This structure perfectly matches the definition of a Major Shareholding Notification, which reports when an investor crosses a threshold of significant ownership (usually 5%, 10%, etc.). This corresponds to the filing code MRQ (Major Shareholding Notification).
2025-06-24 Swedish
KOMMUNIKÉ FRÅN ÅRSSTÄMMA DEN 14 MAJ 2025 I IMMUNOVIA AB (PUBL)
AGM Information Classification · 1% confidence The document is explicitly titled "KOMMUNIKÉ FRÅN ÅRSSTÄMMA DEN 14 MAJ 2025 I IMMUNOVIA AB (PUBL)" which translates to 'COMMUNIQUÉ FROM THE ANNUAL GENERAL MEETING ON MAY 14, 2025, IN IMMUNOVIA AB (PUBL)'. The content details the resolutions passed at the meeting, including approval of accounts, discharge of directors, election of board members and auditors, approval of the remuneration report, and crucially, decisions regarding new share/option programs. This content perfectly matches the definition of materials shared during an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R.
2025-05-14 Swedish
BULLETIN FROM THE ANNUAL GENERAL MEETING ON 14 MAY 2025 IN IMMUNOVIA AB (PUBL)
AGM Information Classification · 1% confidence The document is explicitly titled "BULLETIN FROM THE ANNUAL GENERAL MEETING ON 14 MAY 2025 IN IMMUNOVIA AB (PUBL)" and summarizes the resolutions adopted during that meeting, including the adoption of accounts, election of directors, approval of remuneration reports, and authorization for share/warrant issues. This content directly corresponds to the materials and outcomes of an Annual General Meeting. Therefore, the appropriate classification is AGM-R (AGM Information).
2025-05-14 English
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 1% confidence The document is titled 'DELÅRSRAPPORT Januari-mars 2025' (Interim Report January-March 2025) for Immunovia AB. It contains comprehensive financial statements, including the income statement, balance sheet, cash flow statement, and management commentary on the company's performance for the first quarter of 2025. It is clearly a quarterly financial report, not an announcement of a report or a simple regulatory filing. Q1 2025
2025-05-14 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 1% confidence The document is titled 'INTERIM REPORT January-March 2025' and contains comprehensive financial statements, including consolidated income statements, balance sheets, cash flow statements, and management commentary on the company's performance for the first quarter of 2025. It meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. Q1 2025
2025-05-14 English
Director's Dealing 2025
Director's Dealing Classification · 1% confidence The document details a change in shareholding percentage ('Andel') for an entity (Avanza Bank Holding AB) in another company (Immunovia AB). It specifies the transaction reason as 'Nyemission' (New Share Issue) and reports the resulting share count and percentage (11.03837%). This structure, focusing on changes in significant ownership thresholds ('Gränsvärde för antal aktier: 10 %'), is characteristic of a Major Shareholding Notification, often mandated by financial regulators when ownership crosses specific reporting levels. This aligns directly with the definition for Major Shareholding Notification (MRQ).
2025-05-07 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.